calpain and Ischemic-Stroke

calpain has been researched along with Ischemic-Stroke* in 2 studies

Reviews

1 review(s) available for calpain and Ischemic-Stroke

ArticleYear
PSD-95: An Effective Target for Stroke Therapy Using Neuroprotective Peptides.
    International journal of molecular sciences, 2021, Nov-22, Volume: 22, Issue:22

    Therapies for stroke have remained elusive in the past despite the great relevance of this pathology. However, recent results have provided strong evidence that postsynaptic density protein-95 (PSD-95) can be exploited as an efficient target for stroke neuroprotection by strategies able to counteract excitotoxicity, a major mechanism of neuronal death after ischemic stroke. This scaffold protein is key to the maintenance of a complex framework of protein interactions established at the postsynaptic density (PSD) of excitatory neurons, relevant to neuronal function and survival. Using cell penetrating peptides (CPPs) as therapeutic tools, two different approaches have been devised and advanced to different levels of clinical development. First, nerinetide (Phase 3) and AVLX-144 (Phase 1) were designed to interfere with the coupling of the ternary complex formed by PSD-95 with GluN2B subunits of the N-methyl-D-aspartate type of glutamate receptors (NMDARs) and neuronal nitric oxide synthase (nNOS). These peptides reduced neurotoxicity derived from NMDAR overactivation, decreased infarct volume and improved neurobehavioral results in different models of ischemic stroke. However, an important caveat to this approach was PSD-95 processing by calpain, a pathological mechanism specifically induced by excitotoxicity that results in a profound alteration of survival signaling. Thus, a third peptide (TP95

    Topics: Calpain; Cell-Penetrating Peptides; Disks Large Homolog 4 Protein; Humans; Ischemic Stroke; Neuroprotective Agents; Protein Interaction Maps

2021

Other Studies

1 other study(ies) available for calpain and Ischemic-Stroke

ArticleYear
1,8-cineole ameliorates ischaemic brain damage via TRPC6/CREB pathways in rats.
    The Journal of pharmacy and pharmacology, 2021, Jun-08, Volume: 73, Issue:7

    A previous in vitro study reported that the monoterpene oxide 1,8-cineole (cineole) attenuates neuronal caused by oxygen-glucose deprivation/reoxygenation in culture. However, to date, there is no in vivo evidence showing neuroprotective effects of cineole against stroke. This study aimed to investigate whether cineole attenuates cerebral ischaemic damage in rats.. A rat model of middle cerebral artery occlusion (MCAO) followed by 24 h reperfusion was applied. Male rats were treated with oral cineole (100 mg/kg) for 7 consecutive days, then subjected to MCAO surgery. Infarct volume, neurologic deficits, apoptosis and expression levels of all-spectrin breakdown products of 145 kDa (SBDP145), transient receptor potential canonical (subtype) 6 (TRPC6) and phosphorylated CREB (p-CREB) were measured in ischaemic brain tissues.. Cineole treatment significantly reduced infarct volume, neurological dysfunction, neuronal apoptosis, SBDP145 formation and TRPC6 degradation and enhanced p-CREB expression in MCAO rats compared with vehicle treatment. These neuroprotective effects were markedly suppressed by pharmacological inhibition of MEK or CaMKIV signalling.. Our study provides in vivo evidence demonstrating that cineole pretreatment attenuates ischaemic stroke-induced brain damage, mainly through blocking calpain-induced TRPC6 degradation and activating CREB via MEK/CREB and CaMKIV/CREB signalling pathways.

    Topics: Animals; Apoptosis; Calpain; Cyclic AMP Response Element-Binding Protein; Eucalyptol; Ischemic Stroke; Nervous System Diseases; Neuroprotective Agents; Rats; Signal Transduction; Spectrin; Treatment Outcome; TRPC Cation Channels

2021